Skip to content

Observational study to assess clinical outcomes and patient satisfaction after multifocal IOL implantation

Observational study to assess clinical outcomes and patient satisfaction after multifocal IOL implantation

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
DRKS
Registry ID
DRKS00010108
Enrollment
30
Registered
2016-03-02
Start date
2016-03-02
Completion date
Unknown
Last updated
2025-04-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

patient satisfaction after implantation of a multi-focal IOL

Interventions

Group 1: patient satisfaction of patients with bifocal IOL (VFQ-25, VA) Group 2: patient satisfaction of patients with trifocal IOL (VFQ-25, VA)

Sponsors

Optana GmbH
Lead Sponsor

Eligibility

Sex/Gender
All
Age
45 Years to 75 Years

Inclusion criteria

Inclusion criteria: Patients must have read, understood and signed the Patient Information (Informed Consent Form) Patients that underwent uneventful refractive surgery (LASIK, PRK) after cataract surgery can be included Only patients that underwent uneventful cataract surgery with a bilateral implantation of multifocal IOL

Exclusion criteria

Exclusion criteria: Existing posterior capsule opacity (PCO) at the day of study examination The time between the surgeries of both eyes is maximum 3 months Clinically significant glaucoma Clinically significant macular degeneration, clinically significant macular edema or proliferative diabetic retinopathy Patients with keratoconus or keratectasia Patients who are pregnant or nursing Abnormal examination results from slit lamp, fundus examination or IOL Master, topography, age related changes are acceptable Patients who do not give informed consent

Design outcomes

Secondary

MeasureTime frame
patient satisfaction is determined 6-24 months post-op using the VFQ-25

Primary

MeasureTime frame
mesopic constrast sensitivity 6-24 months post-op

Countries

Spain

Contacts

Public ContactAnne Kroker

Optana GmbH

a.kroker@optana.de+491608548809

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Feb 4, 2026